hero image
Erin E. Boh, MD - Tulane University. New Orleans, LA, US

Erin E. Boh, MD Erin E. Boh, MD

Joseph Chastain Endowed Chair of Clinical Dermatology, Professor & Chairman | Tulane University


Dr. Boh focuses on phototherapy, psoriasis, lymphomas, cosmetic dermatology, sclerotherapy, skin cancers and aging skin.






Dr. Erin Boh - Tulane Health System



Dr. Boh received her B.S. from Auburn University in 1974. She completed her Ph.D. studies in 1980 under Dr. Richard Steele at Tulane University, Department of Biochemistry. She then completed a year-long fellowship with the American Heart Association. Dr. Boh entered the Tulane University School of Medicine in 1981 and received her M.D. in 1985. She completed her internship at Tulane University/Charity Hospital Affiliated Programs in 1986 and completed a Dermatology Residency at UTSW/Parkland Hospital in 1989. In 1989 she was Chief Resident of her Dermatology Program. Dr. Boh joined the Tulane faculty in 1990 as an Assistant Professor and is now an Professor of Dermatology. Dr. Boh's research has focused on chronic diseases such as psoriasis, atopic dermatitis , immunobullous diseases and skin cancers such as lymphoma. She has done research in cutaneous T-Cell lymphomas, lupus and cutaneous manifestations of internal disease, both in the pediatric and adult population. In addition to participating in a number of studies in lymphoma, Dr. Boh has conducted studies on psoriasis and other chronic dermatologic diseases. Dr Boh has held leadership positions in the American Academy of Dermatology ( AAD) and the National Psoriasis Foundation. Dr Boh has been selects as Top Doctors in America for many years and is on the Best Doctors in America as well as in the state. Dr. Boh is certified by the American Board of Dermatology.

Areas of Expertise (5)

Skin Cancer

Psoriasis and Psoriatic Arthritis




Education (3)

Tulane University: Ph.D.

Tulane University: M.D.

Auburn University: B.S.

Media Appearances (3)

8 Ways to Stress Less With Psoriasis

Everyday Health  


Stress is known to exacerbate a number of conditions and can aggravate psoriasis in some people, says Erin Boh, MD, a dermatologist at Tulane University in New Orleans and a member of the National Psoriasis Foundation board. In fact, your first bout of psoriasis can even coincide with a particularly stressful situation in your life — according to an Indian study of 50 people with psoriasis, 26 percent had a stressful life event in the year before their first bout or a serious flare of psoriasis...

view more

One of My Toughest Cases

New Orleans Magazine  


Dr. Erin Boh frequently sees patients with debilitating skin diseases. Generally, the case is a straightforward incidence of eczema, psoriasis or any number of cutaneous diseases. However, sometimes a patient walks in with a rash that’s a complete mystery...

view more

13 Sunburn Myths That Are Damaging Your Skin

Reader's Digest  

“Sunscreens are helpful for even dark-skinned individuals,” says Erin Boh, MD, PhD, FAAD, chair and professor of dermatology at Tulane University School of Medicine. “And remember that children can get sunburned despite their skin color. I advise all patients to use at least an SPF 30 sunscreen or a physical barrier such as zinc or titanium oxide.” Don’t miss the other habits that raise your risk of sun damage...

view more

Articles (2)

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

Journal of the American Academy of Dermatology

Armstrong AW, Siegel MP, Bagel J, Boh EE, et al.

2016 An urgent need exists in the United States to establish treatment goals in psoriasis.

view more

Treatment of refractory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin

Dermatologic Therapy

Liszewski W, Wisniewski JD, Safah H, Boh EE

2014 Necrobiotic xanthogranuloma (NXG) is a disease of fibrotic or telangiectatic granulomatous papules and nodules that can ultimately progress into ulcerated plaques. Although the exact cause of NXG is unknown, it most often occurs in patients with paraproteinemia secondary to a hematologic disease. Consequently, therapy for NXG is targeted at treating the underlying hematologic disease, and subsequent paraproteinemia, with alkylating agents, antimetabolites, radiation, and/or immunosuppressive agents...

view more